


Ask a doctor about a prescription for KALYDECO 75 mg granules in sachet
Package Leaflet: Information for the Patient
Kalydeco 13.4mg granules in sachet
Kalydeco 25 mg granules in sachet
Kalydeco 50 mg granules in sachet
Kalydeco 59.5mg granules in sachet
Kalydeco 75 mg granules in sachet
ivacaftor
Read this package leaflet carefully before your child starts taking this medicine, because it contains important information for your child.
Contents of the package leaflet
Kalydeco contains the active substance ivacaftor. Ivacaftor acts on the cystic fibrosis transmembrane conductance regulator (CFTR), a protein that forms a channel on the cell surface that allows particles such as chloride to enter and leave the cell. Due to mutations in the CFTRgene (see below), chloride movement is reduced in people with cystic fibrosis (CF). Ivacaftor helps certain abnormal CFTR proteins to open more frequently to improve chloride entry and exit from the cell.
Kalydeco granules are indicated:
Do not give Kalydeco to your child
Warnings and precautions
Consult your child's doctor before they start taking Kalydeco.
Children
This medicine should not be given to children under 1 month, as it is not known if ivacaftor is safe and effective in these children.
This medicine should not be given in combination with ivacaftor/tezacaftor/elexacaftor to children under 2 years, as it is not known if ivacaftor is safe and effective in them.
Other medicines and Kalydeco
Tell your child's doctor or pharmacist if your child is using, has recently used, or might use any other medicines. Some medicines may affect the way Kalydeco works or make it more likely to have side effects. In particular, tell your child's doctor if your child is taking any of the following medicines. Your child's doctor may decide to adjust the dose or that your child needs more check-ups.
Taking Kalydeco with food and drinks
Avoid giving your child foods or drinks that contain grapefruit during treatment with Kalydeco, as they may increase the side effects of Kalydeco by increasing the amount of ivacaftor in your child's body.
Driving and using machines
Kalydeco may make your child dizzy. If your child feels dizzy, it is recommended that they do not ride a bike or perform any activity that requires their full attention.
Kalydeco contains lactose and sodium.
If your child's doctor has told your child that they have an intolerance to certain sugars, consult with them before your child takes this medicine.
Kalydeco contains less than 1 mmol of sodium (23 mg) per dose; this is essentially "sodium-free".
Follow the instructions for administration of this medicine exactly as prescribed by your child's doctor. If you are unsure, consult your child's doctor again.
Your child's doctor will determine the correct dose for your child. Your child should continue to use all their other medicines, unless their doctor tells them to stop taking any.
Table 1 provides the recommended dosing recommendations for Kalydeco.
Table1: Recommended dosing recommendations

Administer the morning dose granules and the evening dose granules to your child 12 hours apart.
If your child has liver problems, it may be necessary for their doctor to reduce the dose of Kalydeco, as their liver may not eliminate the medicine from their body as quickly as in children with normal liver function.
Kalydeco should be taken orally.
Each sachet is for single use only.
Administration of Kalydeco to your child:
Fat-containing foods or snacks include those prepared with butter or oils or those that contain eggs. Other fat-containing foods are:
If your child takes more Kalydeco than they should
Your child may experience side effects, including those mentioned in section 4 below. If this happens, consult your child's doctor or pharmacist. If possible, show them your child's medicine and this package leaflet.
If you forget to give Kalydeco to your child
Give the missed dose if it has been less than 6 hours since the time your child was supposed to take the dose. Otherwise, wait until it is time for the next dose. Do not give a double dose to make up for missed doses.
If you interrupt treatment with Kalydeco for your child
Give Kalydeco to your child for as long as their doctor recommends. Do not stop treatment unless their doctor tells you to. If you have any further questions on the use of this medicine, ask your child's doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Stomach pain (abdominal) and increased liver enzymes in the blood.
Possible signs of liver problems
Increased liver enzymes in the blood are common in patients with CF and have also been reported in patients taking Kalydeco alone or in combination with ivacaftor/tezacaftor/elexacaftor.
In patients taking Kalydeco in combination with ivacaftor/tezacaftor/elexacaftor,liver damage and worsening of liver functionhave been reported in people with severe liver disease. Worsening of liver function can be severe and may require a transplant.
The following may be signs of liver problems:
Depression
Signs of depression include a sad or changed mood, anxiety, or feeling of emotional distress.
Tell your child's doctor immediatelyif they experience any of these side effects.
Very common side effects(may affect more than 1 in 10 people)
Common side effects(may affect up to 1 in 10 people)
Uncommon side effects(may affect up to 1 in 100 people)
Frequency not known(cannot be estimated from the available data)
Additional side effects in children and adolescents
The side effects observed in children and adolescents are similar to those observed in adults. However, increased liver enzymes in the blood are more common in young children.
Reporting of side effects
If your child experiences any side effects, consult your child's doctor or pharmacist, even if they are not listed in this package leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, blister and sachet after EXP. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Once mixed, the mixture has been shown to be stable for one hour.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Kalydeco Composition
Kalydeco 13.4 mg granules in sachet:
Each sachet contains 13.4 mg of ivacaftor.
Kalydeco 25 mg granules in sachet:
Each sachet contains 25 mg of ivacaftor.
Kalydeco 50 mg granules in sachet:
Each sachet contains 50 mg of ivacaftor.
Kalydeco 59.5 mg granules in sachet:
Each sachet contains 59.5 mg of ivacaftor.
Kalydeco 75 mg granules in sachet:
Each sachet contains 75 mg of ivacaftor.
The other components are: anhydrous colloidal silica, sodium croscarmellose, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, mannitol, sucralose, and sodium lauryl sulfate (E487).
See the end of section 2: Kalydeco contains lactose and sodium.
Product Appearance and Package Contents
Kalydeco 13.4 mg granules in sachet is a white to off-white granule.
Kalydeco 25 mg granules in sachet is a white to off-white granule.
Kalydeco 50 mg granules in sachet is a white to off-white granule.
Kalydeco 59.5 mg granules in sachet is a white to off-white granule.
Kalydeco 75 mg granules in sachet is a white to off-white granule.
The granules are supplied in sachets.
Kalydeco 13.4 mg granules in sachet, Kalydeco 25 mg granules in sachets, Kalydeco 50 mg granules in sachets, and Kalydeco 75 mg granules in sachet:
Package size of 56 sachets (contains 4 individual cartons with 14 sachets each).
Kalydeco 13.4 mg granules in sachet, Kalydeco 59.5 mg granules in sachet, and Kalydeco 75 mg granules in sachet:
Package size of 28 sachets (contains 4 individual cartons with 7 sachets each).
Marketing Authorization Holder
Vertex Pharmaceuticals (Ireland) Limited
Unit 49, Block 5, Northwood Court, Northwood Crescent
Dublin 9, D09 T665,
Ireland
Tel.: +353 (0)1 761 7299
Manufacturer
Almac Pharma Services (Ireland) Limited
Finnabair Industrial Estate
Dundalk
Co. Louth
A91 P9KD
Ireland
Almac Pharma Services Limited
Seagoe Industrial Estate
Craigavon
County Armagh
BT63 5UA
United Kingdom
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
|
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for KALYDECO 75 mg granules in sachet – subject to medical assessment and local rules.